Hertz Car Sales joins Amazon Autos platform for vehicle sales
Investing.com - H.C. Wainwright has reiterated its Buy rating and $75.00 price target on Legend Biotech Corp . (NASDAQ:LEGN) following strong quarterly sales data for its cancer therapy CARVYKTI. According to InvestingPro data, analysts maintain a Strong Buy consensus with price targets ranging from $54 to $94, while the stock’s current Fair Value analysis suggests it remains undervalued.
Janssen, a division of Johnson & Johnson and Legend’s partner, reported second-quarter 2025 aggregate sales of $439 million for CARVYKTI, representing an 18% quarter-over-quarter increase from $369 million in the first quarter of 2025.
The reported sales exceeded Street consensus estimates of $419 million, with Legend Biotech recording half of this amount based on its 50/50 profit-sharing agreement with Janssen.
H.C. Wainwright noted that CARVYKTI revenues were positively impacted by market share gains, capacity expansion, and international growth, calling the continued double-digit sequential growth "particularly impressive" as sales volume increases.
The firm maintained its full-year 2025 projection for Legend’s CARVYKTI revenue at $985 million, which would represent 104% annual growth compared to 2024, while its third-quarter 2025 estimate stands at $266 million, implying 21% quarterly growth versus the second quarter.
In other recent news, Legend Biotech has reported strong preliminary second-quarter sales for its cancer therapy Carvykti, generating $439 million, a 19% increase from the previous quarter and a 136% rise year-over-year. These sales exceeded both company and Goldman Sachs estimates, with the latter maintaining a Buy rating and a price target of $74.51. The U.S. market contributed $358 million to these sales, while international markets, mainly Europe, showed significant growth. UBS, however, has lowered its price target for Legend Biotech to $54 from $60, citing growth concerns but maintaining a Buy rating. Meanwhile, H.C. Wainwright reiterated a Buy rating and a $75 price target following FDA updates that ease restrictions on Carvykti, potentially accelerating its adoption. Recent study findings presented at the ASCO Annual Meeting revealed that one-third of patients treated with Carvykti remained progression-free for at least five years. RBC Capital continues to rate Legend Biotech as Outperform, with a price target of $78, despite acknowledging competitive challenges. The firm believes Carvykti’s effectiveness and safety profile could drive broader adoption and growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.